The Food and Drug Administration is considering a much-debated new treatment for Lou Gehrig’s disease, a deadly neurological ...
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
WASHINGTON--Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated ...
Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate VG-3927 to proceed with a partial clinical hold related to the maximum drug ...
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Sep. 22, 2023 — Research reveals new non-coding genetic variants associated with Alzheimer's disease functioning in microglia -- brain cells already implicated in the progression of this often ...
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and US pharmaceutical companies. It is the first drug for treatment of the disease ...
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
Valene Campbell started to have a sinking feeling as she was standing in the security line at the airport. It was fall 2016, and she was headed to London for a birthday celebration. But Campbell ...
Sep. 22, 2023 — Research reveals new non-coding genetic variants associated with Alzheimer's disease functioning in microglia -- brain cells already implicated in the progression of this often ...
